S&P 500   4,270.45 (-0.41%)
DOW   33,328.29 (-0.53%)
QQQ   358.86 (+0.16%)
AAPL   173.13 (+1.12%)
MSFT   318.18 (+0.77%)
META   303.54 (+1.11%)
GOOGL   133.02 (+1.65%)
AMZN   128.72 (+1.26%)
TSLA   250.67 (+0.18%)
NVDA   446.80 (+2.72%)
NIO   8.78 (-2.88%)
BABA   86.25 (-0.56%)
AMD   102.73 (-0.09%)
T   14.82 (-1.33%)
F   12.25 (-1.37%)
MU   67.62 (-0.60%)
CGC   0.75 (-3.73%)
GE   108.63 (-1.74%)
DIS   81.16 (+0.14%)
AMC   7.96 (-0.38%)
PFE   33.56 (+1.18%)
PYPL   58.12 (-0.58%)
NFLX   378.72 (+0.30%)
S&P 500   4,270.45 (-0.41%)
DOW   33,328.29 (-0.53%)
QQQ   358.86 (+0.16%)
AAPL   173.13 (+1.12%)
MSFT   318.18 (+0.77%)
META   303.54 (+1.11%)
GOOGL   133.02 (+1.65%)
AMZN   128.72 (+1.26%)
TSLA   250.67 (+0.18%)
NVDA   446.80 (+2.72%)
NIO   8.78 (-2.88%)
BABA   86.25 (-0.56%)
AMD   102.73 (-0.09%)
T   14.82 (-1.33%)
F   12.25 (-1.37%)
MU   67.62 (-0.60%)
CGC   0.75 (-3.73%)
GE   108.63 (-1.74%)
DIS   81.16 (+0.14%)
AMC   7.96 (-0.38%)
PFE   33.56 (+1.18%)
PYPL   58.12 (-0.58%)
NFLX   378.72 (+0.30%)
S&P 500   4,270.45 (-0.41%)
DOW   33,328.29 (-0.53%)
QQQ   358.86 (+0.16%)
AAPL   173.13 (+1.12%)
MSFT   318.18 (+0.77%)
META   303.54 (+1.11%)
GOOGL   133.02 (+1.65%)
AMZN   128.72 (+1.26%)
TSLA   250.67 (+0.18%)
NVDA   446.80 (+2.72%)
NIO   8.78 (-2.88%)
BABA   86.25 (-0.56%)
AMD   102.73 (-0.09%)
T   14.82 (-1.33%)
F   12.25 (-1.37%)
MU   67.62 (-0.60%)
CGC   0.75 (-3.73%)
GE   108.63 (-1.74%)
DIS   81.16 (+0.14%)
AMC   7.96 (-0.38%)
PFE   33.56 (+1.18%)
PYPL   58.12 (-0.58%)
NFLX   378.72 (+0.30%)
S&P 500   4,270.45 (-0.41%)
DOW   33,328.29 (-0.53%)
QQQ   358.86 (+0.16%)
AAPL   173.13 (+1.12%)
MSFT   318.18 (+0.77%)
META   303.54 (+1.11%)
GOOGL   133.02 (+1.65%)
AMZN   128.72 (+1.26%)
TSLA   250.67 (+0.18%)
NVDA   446.80 (+2.72%)
NIO   8.78 (-2.88%)
BABA   86.25 (-0.56%)
AMD   102.73 (-0.09%)
T   14.82 (-1.33%)
F   12.25 (-1.37%)
MU   67.62 (-0.60%)
CGC   0.75 (-3.73%)
GE   108.63 (-1.74%)
DIS   81.16 (+0.14%)
AMC   7.96 (-0.38%)
PFE   33.56 (+1.18%)
PYPL   58.12 (-0.58%)
NFLX   378.72 (+0.30%)
NYSE:QGEN

Qiagen (QGEN) Stock Forecast, Price & News

$39.84
-0.66 (-1.63%)
(As of 01:21 PM ET)
Compare
Today's Range
$39.74
▼
$40.20
50-Day Range
$39.13
▼
$47.22
52-Week Range
$38.98
▼
$51.18
Volume
789,322 shs
Average Volume
967,242 shs
Market Capitalization
$9.08 billion
P/E Ratio
27.10
Dividend Yield
N/A
Price Target
$51.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Qiagen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
27.5% Upside
$51.00 Price Target
Short Interest
Healthy
1.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.29mentions of Qiagen in the last 14 days
Based on 23 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
5.31%
From $2.07 to $2.18 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

100th out of 969 stocks

Biological Products, Except Diagnostic Industry

9th out of 161 stocks

See Top Rated MarketRank™ Stocks Here

QGEN stock logo

About Qiagen (NYSE:QGEN) Stock

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

QGEN Price History

QGEN Stock News Headlines

October 2, 2023 | finance.yahoo.com
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
October 1, 2023 | americanbankingnews.com
Qiagen (NYSE:QGEN) Price Target Cut to $57.00
October 2, 2023 | PressReach (Ad)
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
September 30, 2023 | americanbankingnews.com
Short Interest in Qiagen (NYSE:QGEN) Declines By 16.1%
September 29, 2023 | finanznachrichten.de
QIAGEN N.V.: QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness
September 29, 2023 | americanbankingnews.com
FY2025 Earnings Estimate for Qiagen (NYSE:QGEN) Issued By Zacks Research
September 28, 2023 | markets.businessinsider.com
QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness
September 28, 2023 | finanznachrichten.de
QIAGEN N.V.: QIAGEN reports progress toward achieving Environmental, Social and Governance goals in 2022 Sustainability Report
October 2, 2023 | PressReach (Ad)
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
September 28, 2023 | markets.businessinsider.com
QIAGEN: Kidney Specialists In Tunisia Recommends QuantiFERON Immune-response Tests
September 27, 2023 | finance.yahoo.com
QIAGEN reports progress toward achieving Environmental, Social and Governance goals in 2022 Sustainability Report
September 27, 2023 | msn.com
Citigroup Reiterates Qiagen (QGEN) Buy Recommendation
September 27, 2023 | americanbankingnews.com
Qiagen's (QGEN) "Buy" Rating Reaffirmed at Citigroup
September 27, 2023 | americanbankingnews.com
Qiagen (NYSE:QGEN) Receives $49.50 Average Target Price from Brokerages
September 26, 2023 | finance.yahoo.com
QIAGEN (QGEN) Extends QIAwave Product Line With New Kit
September 26, 2023 | finanznachrichten.de
QIAGEN N.V.: QIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kits
September 26, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Coherus Biosciences (CHRS), Qiagen (QGEN)
September 25, 2023 | finance.yahoo.com
QIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kits
September 25, 2023 | americanbankingnews.com
Qiagen (NYSE:QGEN) Receives $49.50 Consensus Price Target from Analysts
September 13, 2023 | msn.com
Baird Initiates Coverage of Qiagen (QGEN) with Outperform Recommendation
September 12, 2023 | finance.yahoo.com
QIAGEN's (QGEN) New API Streamlines Access to BKB Data
September 9, 2023 | msn.com
Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold
September 4, 2023 | finance.yahoo.com
Qiagen N.V. (NYSE:QGEN) is largely controlled by institutional shareholders who own 82% of the company
August 22, 2023 | markets.businessinsider.com
Berenberg Bank Reaffirms Their Buy Rating on Qiagen (QGEN)
August 18, 2023 | markets.businessinsider.com
Qiagen (QGEN) Receives a Buy from Citi
August 18, 2023 | markets.businessinsider.com
DZ BANK AG Sticks to Their Buy Rating for Qiagen (QGEN)
August 18, 2023 | markets.businessinsider.com
Qiagen (QGEN) was downgraded to a Hold Rating at Berenberg Bank
See More Headlines
Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Company Calendar

Last Earnings
8/08/2023
Today
10/02/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:QGEN
CUSIP
N/A
CIK
1015820
Web
www.qiagen.com
Phone
(177) 355-6600
Fax
31-77-355-6658
Employees
6,178
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$51.00
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+25.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$1.47
Trailing P/E Ratio
27.55
Forward P/E Ratio
19.57
P/E Growth
9.8
Net Income
$423.21 million
Net Margins
17.04%
Pretax Margin
20.86%
Return on Equity
13.72%
Return on Assets
7.54%

Debt

Debt-to-Equity Ratio
0.38
Current Ratio
2.36
Quick Ratio
1.96

Sales & Book Value

Annual Sales
$2.14 billion
Price / Sales
4.31
Cash Flow
$3.47 per share
Price / Cash Flow
11.68
Book Value
$15.22 per share
Price / Book
2.66

Miscellaneous

Outstanding Shares
228,000,000
Free Float
207,480,000
Market Cap
$9.23 billion
Optionable
Optionable
Beta
0.37
10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Thierry Bernard (Age 58)
    CEO, MD & Member of Management Board
    Comp: $2.67M
  • Dr. Roland Sackers (Age 54)
    CFO, MD & Member of Management Board
    Comp: $1.33M
  • Mr. Antonio Santos
    Sr. VP & Head of Global Operations
  • Mr. John Gilardi
    VP of Corp. Communications & Investor Relations
  • Ms. Stephany Foster (Age 44)
    Sr. VP & Head of HR
  • Dr. Thomas Schweins
    Sr. VP of Life Science Bus. Area
  • Dr. Thomas Theuringer
    Sr. Director & Head of External Communications
  • Mr. Jean-Pascal Viola
    Sr. VP & Head of Molecular Diagnostics Bus. Area
  • Dr. Jonathan G. Sheldon Ph.D. (Age 51)
    Sr. VP of Qiagen Digital Insights Bus. Area
  • Mr. Thomas Neidert
    VP of Global Treasury

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













QGEN Stock - Frequently Asked Questions

Should I buy or sell Qiagen stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" QGEN shares.
View QGEN analyst ratings or view top-rated stocks.

What is Qiagen's stock price forecast for 2023?

6 brokerages have issued twelve-month price objectives for Qiagen's shares. Their QGEN share price forecasts range from $40.00 to $60.00. On average, they expect the company's stock price to reach $51.00 in the next year. This suggests a possible upside of 25.9% from the stock's current price.
View analysts price targets for QGEN or view top-rated stocks among Wall Street analysts.

How have QGEN shares performed in 2023?

Qiagen's stock was trading at $49.87 at the beginning of the year. Since then, QGEN shares have decreased by 18.8% and is now trading at $40.50.
View the best growth stocks for 2023 here.

Are investors shorting Qiagen?

Qiagen saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 3,240,000 shares, a decrease of 16.1% from the August 31st total of 3,860,000 shares. Based on an average daily trading volume, of 1,250,000 shares, the days-to-cover ratio is currently 2.6 days. Approximately 1.4% of the company's stock are short sold.
View Qiagen's Short Interest.

When is Qiagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our QGEN earnings forecast.

How were Qiagen's earnings last quarter?

Qiagen (NYSE:QGEN) announced its quarterly earnings data on Tuesday, August, 8th. The company reported $0.51 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.01. The business earned $497 million during the quarter, compared to the consensus estimate of $492.21 million. Qiagen had a trailing twelve-month return on equity of 13.72% and a net margin of 17.04%. Qiagen's revenue was down 8.6% on a year-over-year basis. During the same period last year, the firm earned $0.51 EPS.

What ETFs hold Qiagen's stock?

ETFs with the largest weight of Qiagen (NYSE:QGEN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Newday Ocean Health ETF (AHOY), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX), WisdomTree U.S. AI Enhanced Value Fund (AIVL) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of $2.07- for the period, compared to the consensus earnings per share estimate of $2.11. The company issued revenue guidance of $1.97B-, compared to the consensus revenue estimate of $2.05 billion.

What is Thierry Bernard's approval rating as Qiagen's CEO?

33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

How do I buy shares of Qiagen?

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $40.50.

How much money does Qiagen make?

Qiagen (NYSE:QGEN) has a market capitalization of $9.23 billion and generates $2.14 billion in revenue each year. The company earns $423.21 million in net income (profit) each year or $1.47 on an earnings per share basis.

How many employees does Qiagen have?

The company employs 6,178 workers across the globe.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The official website for the company is www.qiagen.com. The company can be reached via phone at (177) 355-6600, via email at ir@qiagen.com, or via fax at 31-77-355-6658.

This page (NYSE:QGEN) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -